For laboratory use only. This product is intended for animal research only and not for use in humans.
VivoTag® 680 XL Fluorochrome, at a wavelengh 680 nm, is a amine-reactive near-infrared fluorochrome for coupling via an NHS ester linkage to peptides, small molecules, proteins, antibodies, nanoparticles or other macromolecules. Hydrolytically stable and low self quenching for higher loading applications. Quanitiy = 1 mg.
“For laboratory use only. This product is intended for animal research only and not for use in humans.”
Get a quote or request more information on any of our reagents.
Additional Resources
In Vivo University
In Vivo Reagents Citations Library
In Vivo Imaging Systems & Software
| Fluorescent Agent Type | Labeling |
|---|---|
| Optical Imaging Classification | Fluorescence Imaging |
| Product Brand Name | VivoTag |
| Shipping Condition | Blue Ice |
| Unit Size | 1 mg |
| Wave Length | 680 nm |
,VivoTag® 680 XL is a near infrared fluorescent imaging labeling agent containing an N-hydroxysuccinimide (NHS)-ester. Labeling reagents, such as VivoTag 680 XL are commonly used for labeling proteins. The NHS ester moiety reacts with amino groups to form amide bonds. Lysines within proteins, including antibodies, are available as targets for this chemical conjugation.,Protein labeling efficiency may vary depending upon the type of protein labeled, so different conjugation ratios may need to be attempted to attain success. For near infrared fluorophore conjugation, ratios of fluorophore to protein of 4:1 have been seen to generate effective imaging agents. Not all antibodies or proteins (independent of target specificity) make good imaging agents, due to long half-lives and/or excessive accumulation in non-target sites.
Complete suite of in vivo fluorescence tomography imaging solutions from PerkinElmer lets you discover more about biological targets, processes and pathways, directly in the living animal.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.
